Based on the new investor slides and today's interview, it seems like they may also try to market leronlimab with current HIV drugs to prevent liver fibrosis. Maybe I am reading into it too much, but many HIV drugs result in fibrosis and NP stated leronlimab "could have dual effect, fibrosis and HIV"....."most regiments have liver problems"......"leronlimab has to be part of all the regiments if you want to stop fibrosis and if we prove that in clinical setting we will remain for anybody to chose for their regiment"